Biologics and Donor Bone Marrow Cells for Targeted Immunomodulation in Vascularized Composite Allotransplantation: A Translational Trial in Swine

2011 ◽  
Vol 43 (9) ◽  
pp. 3541-3544 ◽  
Author(s):  
G.S. Wachtman ◽  
E.G. Wimmers ◽  
V.S. Gorantla ◽  
C.-H. Lin ◽  
S. Schneeberger ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Vascularized Composite Allotransplantation ◽  
Donor Bone Marrow ◽  
Marrow Cells

MP41-03 FIVE-YEAR CLINICAL EFFECTS OF DONOR BONE MARROW CELLS INFUSIONS IN KIDNEY ALLOGRAFT RECIPIENTS

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Ghasem Solgi ◽  
Vijayakrishna Gadi ◽  
Gholamreza Pourmand ◽  
Abdolrasoul Mehrsai ◽  
Moslem Ranjbar ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Clinical Effects ◽  
Kidney Allograft ◽  
Donor Bone Marrow ◽  
Marrow Cells

scholarly journals Host Conditioning With 5-Fluorouracil and kit-Ligand to Provide for Long-Term Bone Marrow Engraftment

Blood ◽  
1997 ◽  
Vol 89 (7) ◽  
pp. 2376-2383 ◽  
Author(s):  
Ronald van Os ◽  
Donald Dawes ◽  
John M.K. Mislow ◽  
Alice Witsell ◽  
Peter M. Mauch
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Mixed Chimerism ◽  
Kit Ligand ◽  
Donor Bone Marrow ◽  
Before And After ◽  
Total Body ◽  
Marrow Cells

Abstract Administration of kit-ligand (KL) before and after doses of 5-fluorouracil (5-FU) results in marrow failure in mice, presumably because of enhanced KL-induced cycling of stem cells, which makes them more susceptible to the effects of 5-FU. In attempt to capitalize on this effect on stem cells, we studied the ability of KL and 5-FU to allow stable donor engraftment of congenically marked marrow in a C57BL/6 (B6) mouse model. KL was administered subcutaneously at 50 μg/kg, 21 hours and 9 hours before and 3 hours after each of two doses of 5-FU (125 mg/kg) given 7 days apart to B6-recipients. Animals then received three injections of 107 congenic B6-Gpi-1a-donor bone marrow cells at 24, 48, and 72 hours after the second 5-FU dose. A separate group of animals received a single dose of either 1 × 107 or 3 × 107 donor marrow cells 24 hours after the last 5-FU dose. The level of engraftment was measured from Gpi-phenotyping at 1, 3, 6, and 8 months in red blood cells (RBCs) and at 8 months by phenotyping cells from the thymus, spleen, and marrow. Percent donor engraftment in RBCs appeared stable after 6 months. The percent donor engraftment in RBCs at 8 months was significantly higher in KL + 5-FU prepared recipients (33.0 ± 2.7), compared with 5-FU alone (18.5 ± 2.6, P < .0005), or saline controls (17.8 ± 1.7, P < .0001). In an additional experiment, granulocyte colony-stimulating factor (100 μg/dose) was added to a reduced dose of KL (12.5 μg/dose); engraftment was similar to KL alone. At 8 months after transplantation the levels of engraftment in other tissues such as bone marrow, spleen, and thymus correlated well with erythroid engraftment to suggest that multipotent long-term repopulating stem cells had engrafted in these animals. There are concerns for the toxicity of total body irradiation (TBI)- or busulfan-based regimens in young recipients of syngeneic or transduced autologous marrow who are transplanted for correction of genetic disease. In these recipients complete donor engraftment may not be needed. The results with KL and 5-FU are encouraging for the further refinement of non-TBI, nonbusulfan techniques to achieve stable mixed chimerism.

IN VITRO IMMUNOGENICITY OF CADAVER DONOR BONE MARROW CELLS USED FOR THE INDUCTION OF ALLOGRAFT ACCEPTANCE IN CLINICAL TRANSPLANTATION1

1999 ◽  
Vol 68 (8) ◽  
pp. 1172-1180 ◽  
Author(s):  
James M. Mathew ◽  
Manuel Carreno ◽  
Laphalle Fuller ◽  
Camillo Ricordi ◽  
Norma Kenyon ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Donor Bone Marrow ◽  
Cadaver Donor ◽  
Marrow Cells

MP-03.08: Effect of Donor Bone Marrow Cells Infusion on Alloimmunization in Kidney Allograft Patients

Urology ◽  
2009 ◽  
Vol 74 (4) ◽  
pp. S54
Author(s):  
G. Pourmand ◽  
G. Solgi ◽  
A. Mehrsai ◽  
M. Niknam ◽  
M. Ebrahimi Rad ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Kidney Allograft ◽  
Donor Bone Marrow ◽  
Marrow Cells

Presence of bone marrow–derived circulating progenitor endothelial cells in the newly formed lymphatic vessels

Blood ◽  
2005 ◽  
Vol 106 (13) ◽  
pp. 4184-4190 ◽  
Author(s):  
Piotr Religa ◽  
Renhai Cao ◽  
Meit Bjorndahl ◽  
Zhongjun Zhou ◽  
Zhenping Zhu ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Growth Factor ◽  
Fluorescent Protein ◽  
Bone Marrow Cells ◽  
Lymphatic Vessels ◽  
Growth Factor Receptor ◽  
Donor Bone Marrow ◽  
Green Fluorescent ◽  
Corneal Lymphangiogenesis ◽  
Marrow Cells

Bone marrow (BM)-derived circulating endothelial precursor cells (CEPCs) have been reported to incorporate into newly formed blood vessels under physiologic and pathologic conditions. However, it is unknown if CEPCs contribute to lymphangiogenesis. Here we show that in a corneal lymphangiogenesis model of irradiated mice reconstituted with enhanced green fluorescent protein (EGFP)-positive donor bone marrow cells, CEPCs are present in the newly formed lymphatic vessels. Depletion of bone marrow cells by irradiation remarkably suppressed lymphangiogenesis in corneas implanted with fibroblast growth factor-2 (FGF-2). Further, transplantation of isolated EGFP-positive/vascular endothelial growth factor receptor-3-positive (EGFP+/VEGFR-3+) or EGFP+/VEGFR-2+ cell populations resulted in incorporation of EGFP+ cells into the newly formed lymphatic vessels. EGFP+/CEPCs were also present in peritumoral lymphatic vessels of a fibrosarcoma. These data suggest that BM-derived CEPCs may play a role in “lymphvasculogenesis.”

ANTI-CD3 TREATMENT FACILITATES ENGRAFTMENT OF FULL H-2-DISPARATE DONOR BONE MARROW CELLS AND SUBSEQUENT SKIN ALLOGRAFT TOLERANCE

1994 ◽  
Vol 58 (5) ◽  
pp. 610-617 ◽  
Author(s):  
Anneke de Vries-van der Zwan ◽  
Arit C. Besseling ◽  
Femia Kievits ◽  
Esther van Twuyver ◽  
Leo P. de Waal
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Skin Allograft ◽  
Donor Bone Marrow ◽  
Marrow Cells
Sign in / Sign up

Export Citation Format

Share Document